Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan P Buchbinder

Showing results (71-80 of 130) with videos related to

Pageof 13
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|August 24, 2011
Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study)Ruanne V Barnabas, Judith N Wasserheit, Yunda Huang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 23, 2017
Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure ProphylaxisDavid V Glidden, Kathleen Mulligan, Vanessa McMahan, et al.
The Journal of Infectious Diseases|January 1, 2003
Herpes simplex virus type 2 infection as a risk factor for human immunodeficiency virus acquisition in men who have sex with menCristina Renzi, John M Douglas, Mark Foster, et al.
AIDS Care|September 2, 2024
Acceptability of an automated directly observed therapy (DOT) application for PrEP adherence support among young men who have sex with men: a qualitative explorationJennifer Velloza, Albert Y Liu, Ariana W K Katz, et al.
AIDS Patient Care and Stds|November 15, 2014
Medication adherence among men who have sex with men at risk for HIV infection in the United States: implications for pre-exposure prophylaxis implementationAlbert Y Liu, Nancy A Hessol, Eric Vittinghoff, et al.
Plos One|January 15, 2014
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP)Albert Y Liu, Qiyun Yang, Yong Huang, et al.
AIDS (London, England)|January 17, 2019
Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration projectMatthew A Spinelli, David V Glidden, Warren C Rodrigues, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 14, 2013
Sexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United StatesAlbert Y Liu, Eric Vittinghoff, Kata Chillag, et al.
Plos One|April 13, 2012
Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccinationCheng Cheng, Lingshu Wang, LingShu Wang, et al.
Plos One|December 25, 2013
No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxisJulia L Marcus, David V Glidden, Kenneth H Mayer, et al.
Pageof 13

Showing results (71-80 of 130) with videos related to

Sort By:
Pageof 13
Journal of Acquired Immune Deficiency Syndromes (1999)|August 24, 2011
Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study)Ruanne V Barnabas, Judith N Wasserheit, Yunda Huang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 23, 2017
Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure ProphylaxisDavid V Glidden, Kathleen Mulligan, Vanessa McMahan, et al.
The Journal of Infectious Diseases|January 1, 2003
Herpes simplex virus type 2 infection as a risk factor for human immunodeficiency virus acquisition in men who have sex with menCristina Renzi, John M Douglas, Mark Foster, et al.
AIDS Care|September 2, 2024
Acceptability of an automated directly observed therapy (DOT) application for PrEP adherence support among young men who have sex with men: a qualitative explorationJennifer Velloza, Albert Y Liu, Ariana W K Katz, et al.
AIDS Patient Care and Stds|November 15, 2014
Medication adherence among men who have sex with men at risk for HIV infection in the United States: implications for pre-exposure prophylaxis implementationAlbert Y Liu, Nancy A Hessol, Eric Vittinghoff, et al.
Plos One|January 15, 2014
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP)Albert Y Liu, Qiyun Yang, Yong Huang, et al.
AIDS (London, England)|January 17, 2019
Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration projectMatthew A Spinelli, David V Glidden, Warren C Rodrigues, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 14, 2013
Sexual risk behavior among HIV-uninfected men who have sex with men participating in a tenofovir preexposure prophylaxis randomized trial in the United StatesAlbert Y Liu, Eric Vittinghoff, Kata Chillag, et al.
Plos One|April 13, 2012
Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccinationCheng Cheng, Lingshu Wang, LingShu Wang, et al.
Plos One|December 25, 2013
No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxisJulia L Marcus, David V Glidden, Kenneth H Mayer, et al.
Pageof 13